Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific equity transactions.
- Transaction Price: $52.913 per American Depositary Share (ADS).
- Dividend Re-investment Date: January 9, 2014.
Material Changes
The filing details increases in ADS holdings for two individuals due to dividend re-investments:
- Mrs. D P Connelly: Acquired 36.779 ADSs (personal contribution) and 37.654 ADSs (company matching contribution).
- Mr. W C Louv: Acquired 26.978 ADSs (personal contribution) and 27.591 ADSs (company matching contribution).
These transactions relate to bonuses from 2010, 2011, and 2012 on a post-tax basis.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the vesting schedules for the 2010, 2011, and 2012 bonus periods referenced in the plan.
- Confirm the total outstanding ADS count for the named executives following these acquisitions.
- Review the full terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan regarding matching contributions.